Literature DB >> 22297912

Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7-dibromocryptolepine against Leishmania donovani promastigotes.

Sudipta Hazra, Subhalakshmi Ghosh, Sukalyani Debnath, Scott Seville, Vijay Kumar Prajapati, Colin W Wright, Shyam Sundar, Banasri Hazra.   

Abstract

Cryptolepine (5-methyl-10H-indolo [3, 2-b] quinoline), an indoloquinoline alkaloid (1) isolated from a medicinal plant traditionally used in Western Africa for treatment of malaria, has been shown to possess broad spectrum biological activity in addition to its antiplasmodial effect. Here, the antileishmanial properties of 11 synthetic derivatives of cryptolepine against Leishmania donovani parasites have been evaluated for the first time. 2,7-Dibromocryptolepine (8; IC50 0.5 ± 0.1 μM) was found to be the most active analogue against the promastigote form of a classical L. donovani strain (AG83) in comparison to the natural alkaloid, cryptolepine (1; IC50 1.6 ± 0.1 μM). Further, 8 was found to substantially inhibit the intracellular amastigote forms of two clinical isolates, one of them being an SbV-resistant strain of L. donovani. Moreover, the toxicity of 8 against normal mouse peritoneal macrophage cells was markedly lower than that of 1 (IC50 values: 9.0 ± 1.2 and 1.1 ± 0.3 μM, respectively), indicating 8 to be a prospective “lead” towards novel antileishmanial therapy. This was supported by studies on the mechanism of cytotoxicity induced by 8 in L. donovani promastigotes (AG83), which revealed the cytoplasmic and nuclear features of metazoan apoptosis. Light microscopic observation demonstrated a gradual decline in the motility, cell volume, and survival of the treated parasites with increasing incubation time. Flow cytometric analysis of phosphatidylserine externalization and distribution of cells in different phases of cell cycle confirmed the presence of a substantial percentage of cells in early apoptotic stage. Disruption of mitochondrial membrane integrity in terms of depolarization of membrane potential, and finally degradation of chromosomal DNA into oligonucleosomal fragments - the hallmark event of apoptosis - characterized the mode of cell death in L. donovani promastigotes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297912     DOI: 10.1007/s00436-012-2818-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  22 in total

1.  Probing the N-5 region of the indoloquinoline alkaloid, cryptolepine for anticryptococcal activity.

Authors:  S Y Ablordeppey; P Fan; A M Clark; A Nimrod
Journal:  Bioorg Med Chem       Date:  1999-02       Impact factor: 3.641

2.  Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis.

Authors:  Radheshyam Maurya; Sanjana Mehrotra; Vijay Kumar Prajapati; Susanne Nylén; David Sacks; Shyam Sundar
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites.

Authors:  John N Lisgarten; Miquel Coll; Jose Portugal; Colin W Wright; Juan Aymami
Journal:  Nat Struct Biol       Date:  2002-01

5.  Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents.

Authors:  C W Wright; J Addae-Kyereme; A G Breen; J E Brown; M F Cox; S L Croft; Y Gökçek; H Kendrick; R M Phillips; P L Pollet
Journal:  J Med Chem       Date:  2001-09-13       Impact factor: 7.446

6.  Valeriana wallichii root extracts and fractions with activity against Leishmania spp.

Authors:  Subhalakshmi Ghosh; Sukalyani Debnath; Sudipta Hazra; Andreas Hartung; Katja Thomale; Martina Schultheis; Petra Kapkova; Uta Schurigt; Heidrun Moll; Ulrike Holzgrabe; Banasri Hazra
Journal:  Parasitol Res       Date:  2010-11-18       Impact factor: 2.289

Review 7.  Indoloquinolines as scaffolds for drug discovery.

Authors:  J Lavrado; R Moreira; A Paulo
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 8.  Leishmaniasis vaccines: past, present and future.

Authors:  Farrokh Modabber
Journal:  Int J Antimicrob Agents       Date:  2010-08-30       Impact factor: 5.283

9.  Evaluation of anti-leishmanial activity of selected Indian plants known to have antimicrobial properties.

Authors:  Umakant Sharma; Thirumurthy Velpandian; Pawan Sharma; Sarman Singh
Journal:  Parasitol Res       Date:  2009-07-11       Impact factor: 2.289

Review 10.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

View more
  3 in total

1.  Recent Advances in the Chemistry and Pharmacology of Cryptolepine.

Authors:  Steven D Shnyder; Colin W Wright
Journal:  Prog Chem Org Nat Prod       Date:  2021

2.  The efficacy of 2-nitrovinylfuran derivatives against Leishmania in vitro and in vivo.

Authors:  Sergio Sifontes-Rodríguez; Lianet Monzote-Fidalgo; Nilo Castañedo-Cancio; Ana Margarita Montalvo-Álvarez; Yamilé López-Hernández; Niurka Mollineda Diogo; Juan Francisco Infante-Bourzac; Oliver Pérez-Martín; Alfredo Meneses-Marcel; José Antonio Escario García-Trevijano; Miguel Ángel Cabrera-Pérez
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-03-24       Impact factor: 2.743

3.  Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice.

Authors:  Anita Masic; Ana Maria Valencia Hernandez; Sudipta Hazra; Jan Glaser; Ulrike Holzgrabe; Banasri Hazra; Uta Schurigt
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.